Bronchodilator responsiveness over time in SPIROMICS: Clinical characteristics
C. Cooper (Los Angeles, United States of America), S. Fortis (Iowa, United States of America), D. Couper (Chapel Hill, United States of America), M. Quibrera (Chapel Hill, United States of America), M. Arjomandi (San Francisco, United States of America), I. Barjaktarevic (Los Angeles, United States of America), G. Barr (New York, United States of America), S. Bhatt (Birmingham, United States of America), R. Bowler (Denver, United States of America), J. Curtis (Ann Arbor, United States of America), M. Dransfield (Birmingham, United States of America), B. Drummond (Chapel Hill, United States of America), M. Han (Ann Arbor, United States of America), N. Hansel (Baltimore, United States of America), A. Hastie (Winston Salem, United States of America), E. Hoffman (Iowa City, United States of America), R. Kanner (Salt Lake City, United States of America), V. Kim (Philadelphia, United States of America), J. Krishnan (Chicago, United States of America), S. Lazarus (San Francisco, United States of America), F. Martinez (Omaha, United States of America), V. Ortega (Winston Salem, United States of America), R. Paine (Salt Lake City, United States of America), S. Peters (Winston Salem, United States of America), S. Rennard (Omaha, United States of America), D. Tashkin (Los Angeles, United States of America), P. Woodruff (San Francisco, United States of America), W. Anderson (Chapel Hill, United States of America)
Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Cooper (Los Angeles, United States of America), S. Fortis (Iowa, United States of America), D. Couper (Chapel Hill, United States of America), M. Quibrera (Chapel Hill, United States of America), M. Arjomandi (San Francisco, United States of America), I. Barjaktarevic (Los Angeles, United States of America), G. Barr (New York, United States of America), S. Bhatt (Birmingham, United States of America), R. Bowler (Denver, United States of America), J. Curtis (Ann Arbor, United States of America), M. Dransfield (Birmingham, United States of America), B. Drummond (Chapel Hill, United States of America), M. Han (Ann Arbor, United States of America), N. Hansel (Baltimore, United States of America), A. Hastie (Winston Salem, United States of America), E. Hoffman (Iowa City, United States of America), R. Kanner (Salt Lake City, United States of America), V. Kim (Philadelphia, United States of America), J. Krishnan (Chicago, United States of America), S. Lazarus (San Francisco, United States of America), F. Martinez (Omaha, United States of America), V. Ortega (Winston Salem, United States of America), R. Paine (Salt Lake City, United States of America), S. Peters (Winston Salem, United States of America), S. Rennard (Omaha, United States of America), D. Tashkin (Los Angeles, United States of America), P. Woodruff (San Francisco, United States of America), W. Anderson (Chapel Hill, United States of America). Bronchodilator responsiveness over time in SPIROMICS: Clinical characteristics. 1853
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: